The application of accelerator mass spectrometry to absolute bioavailability studies in humans: Simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers

Journal of Clinical Pharmacology

Volumn 45, Issue 10, 2005, Pages 1198-1205

  Sarapa, Nenad ^a,c   Hsyu, Poe Hirr ^a   Lappin, Graham ^b   Garner, Ronald Colin ^b  

^a PFIZER INC   (United States)

^b Xceleron Ltd   (United Kingdom)

^c Daiichi Medical Research   (United States)

Author keywords

Absolute bioavailability; AMS; Human microdosing; Nelfinavir

Indexed keywords

AG 1402; CARBON 14; CHOLESTEROL; DRUG METABOLITE; NELFINAVIR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; LIQUID SCINTILLATION COUNTING; MALE; MASS SPECTROMETRY; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STATISTICAL ANALYSIS; STEADY STATE; TABLET; TRIACYLGLYCEROL BLOOD LEVEL; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; DIARRHEA; HIV PROTEASE INHIBITORS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MIDDLE AGED; NELFINAVIR; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 25444451050     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005280051     Document Type: Article

References (24)

1. Vogel JS, Turteltaub KW, Finkel R, Nelson DE. Accelerator mass spectrometry: isotope quantification at attomole sensitivity. Anal Chem. 1995;67:353A-359A.
2. Bennett CL, Beukens RP, Gover MR, et al. Radiocarbon dating using electrostatic accelerators: negative ions provide the key. Science. 1997;198:508-510.
3. Nelson DE, Korteling RG, Stott WR. Carbon-14: direct detection at natural concentrations. Science. 1997;198:507-508.
4. Felton JS, Turteltaub KW. Accelerator mass spectrometry for measuring low-dose carcinogen binding to DNA. Environ Health Perspect. 1994;102:450-452.
5. Kaye B, Garner RC, Mauthe RJ, Freeman SPHT, Turteltaub KW. A preliminary evaluation of accelerator mass spectrometry in the biomedical field. J Pharm Biomed Anal. 1997;16:541-543.
6. Cupid B, Garner RC. Accelerator mass spectrometry: a new tool for drug metabolism studies. In: Gooderham N, Jenner P, Patterson L, eds. Drug Metabolism: Towards the Next Millenium. Amsterdam: IOS Press; 1998:175-187.
7. Barker J, Garner RC. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun Mass Spectrom. 1999;13:285-293.
8. 14C-Diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci. 2002;91:32-40.
9. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotic. 2001;31:619-632.
10. Turteltaub KW, Felton JS, Gledhill BL, et al. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci USA. 1990;87:5288-5292.
11. Turteltaub KW, Mauthe RJ, Dingley KH, et al. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutation Res. 1997;376:243-252.
12. 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal Bioanal Chem. 2004;378:356-364.
13. 14C-labelled (B)-6-[amino(4-chlorophenyl) (1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Disp. 2002;30:1-8.
14. Sarapa N. Early human microdosing to reduce attrition in clinical drug development. Am Pharm Outsourcing. 2003;4:42-47.
15. Committee for Medicinal Products for Human Use (CHMP). Position Paper on Nonclinical Safety Studies to Support Clinical Trials With a Single Microdose. CHMP/SWP/2599/02/Rev 1. London: European Medicines Agency; 2004.
16. Strong JM, Dutcher JS, Lee WK, Atkinson AJ. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin Pharmacol Ther. 1975;18:613-622.
17. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Beckenridge AM. Pharmacokinetics of primaquine in man: I. Studies of the absolute bioavailability and effects of dose size. Br J Pharmacol. 1985;19:745-750.
18. Hsyu P-H, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45:3445-3450.
19. Investigator's Brochure for VIRACEPT (Nelfinavir Mesylate). Revision VI, A430. San Diego: Pfizer La Jolla Laboratories; 2001.
20. Vogel JS. Rapid production of graphite without contamination for biomedical AMS. Radiocarbon. 1992;34:344-350.
21. Lappin G, Garner RC. Ultra-sensitive detection of radiolabelled drugs and their metabolites using accelerator mass spectrometry. In: Wilson ID, ed. Bioanalytical Separations: Handbook of Analytical Separations. Vol. 4. New York: Elsevier Science; 2003:331-349.
22. Turteltaub KW, Vogel JS. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr Pharm Des. 2000;6:991-1007.
23. VIRACEPT (nelfinavir mesylate) tablets and oral powder [prescribing information]. Available at: http://www.viracept.com/brochures/PI.pdf. December 2002.
24. Food and Drug Administration. Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies. Rockville, Md: Center for Drug Evaluation and Research, FDA; 2005.